BACKGROUND: Although nearly 2 million people live with HIV in Latin America and the Caribbean, mortality rates after initiation of highly active antiretroviral therapy (HAART) have not been well described. METHODS: Five thousand one hundred fifty-two HIV-infected, antiretroviral-naive adults from clinics in Argentina, Brazil, Chile, Haiti, Honduras, Mexico, and Peru starting HAART during 1996-2007 were included. First-year mortality rates and their association with demographics, regimen, baseline CD4, and clinical stage were assessed. RESULTS: Overall 1-year mortality rate was 8.3% [95% confidence interval (CI): 7.6% to 9.1%], although variable across sites: 2.6%, 3.7%, 6.0%, 13.0%, 10.8%, 3.5%, and 9.8% for clinics in Argentina, Brazil, Chile, Haiti, Honduras, Mexico, and Peru, respectively. Eighty percent of deaths occurred within the first 6 months. Median baseline CD4 was 107 cells per milliliter, ranging from 79 (Peru) to 163 (Argentina). Mortality estimates adjusting for CD4 were similar across sites (1.1%-2.8% for CD4 = 200), except for Haiti, 7.5%, and Honduras, 7.0%. Death was associated with lower CD4 [adjusted hazard ratio for CD4 = 200 vs. CD4 = 50 was 0.58; 95% CI: 0.40 to 0.85] and clinical AIDS (hazard ratio = 3.1; 95% CI: 2.1 to 4.5). CONCLUSIONS: Mortality rates were similar to those reported elsewhere for resource-limited settings. Disease stage at HAART initiation, treatment eligibility criteria, program age, and background mortality rates may explain some variability in prognosis between sites.
BACKGROUND: Although nearly 2 million people live with HIV in Latin America and the Caribbean, mortality rates after initiation of highly active antiretroviral therapy (HAART) have not been well described. METHODS: Five thousand one hundred fifty-two HIV-infected, antiretroviral-naive adults from clinics in Argentina, Brazil, Chile, Haiti, Honduras, Mexico, and Peru starting HAART during 1996-2007 were included. First-year mortality rates and their association with demographics, regimen, baseline CD4, and clinical stage were assessed. RESULTS: Overall 1-year mortality rate was 8.3% [95% confidence interval (CI): 7.6% to 9.1%], although variable across sites: 2.6%, 3.7%, 6.0%, 13.0%, 10.8%, 3.5%, and 9.8% for clinics in Argentina, Brazil, Chile, Haiti, Honduras, Mexico, and Peru, respectively. Eighty percent of deaths occurred within the first 6 months. Median baseline CD4 was 107 cells per milliliter, ranging from 79 (Peru) to 163 (Argentina). Mortality estimates adjusting for CD4 were similar across sites (1.1%-2.8% for CD4 = 200), except for Haiti, 7.5%, and Honduras, 7.0%. Death was associated with lower CD4 [adjusted hazard ratio for CD4 = 200 vs. CD4 = 50 was 0.58; 95% CI: 0.40 to 0.85] and clinical AIDS (hazard ratio = 3.1; 95% CI: 2.1 to 4.5). CONCLUSIONS: Mortality rates were similar to those reported elsewhere for resource-limited settings. Disease stage at HAART initiation, treatment eligibility criteria, program age, and background mortality rates may explain some variability in prognosis between sites.
Authors: Evan Wood; Julio S G Montaner; Keith Chan; Mark W Tyndall; Martin T Schechter; David Bangsberg; Michael V O'Shaughnessy; Robert S Hogg Journal: AIDS Date: 2002-10-18 Impact factor: 4.177
Authors: Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: Wafaie W Fawzi; Gernard I Msamanga; Donna Spiegelman; Ruilan Wei; Saidi Kapiga; Eduardo Villamor; Davis Mwakagile; Ferdinand Mugusi; Ellen Hertzmark; Max Essex; David J Hunter Journal: N Engl J Med Date: 2004-07-01 Impact factor: 91.245
Authors: Evan Wood; Robert S Hogg; Benita Yip; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner Journal: Ann Intern Med Date: 2003-11-18 Impact factor: 25.391
Authors: Marco T Luque; Cathy A Jenkins; Bryan E Shepherd; Denis Padgett; Vanessa Rouzier; Regina Célia M Succi; Daisy M Machado; Catherine C McGowan; Sten H Vermund; Jorge A Pinto Journal: J Pediatr Date: 2017-01-09 Impact factor: 4.406
Authors: Mark J Giganti; Paula M Luz; Yanink Caro-Vega; Carina Cesar; Denis Padgett; Serena Koenig; Juan Echevarria; Catherine C McGowan; Bryan E Shepherd Journal: AIDS Res Hum Retroviruses Date: 2015-03-06 Impact factor: 2.205
Authors: Serena P Koenig; Luis A Rodriguez; Courtenay Bartholomew; Alison Edwards; Tracie E Carmichael; Geoffrey Barrow; André Cabié; Robert Hunter; Giselle Vasquez-Mora; Avion Quava-Jones; Nicholas Adomakoh; J Peter Figueroa; Bernard Liautaud; Magaly Torres; Jean W Pape Journal: J Acquir Immune Defic Syndr Date: 2012-04-01 Impact factor: 3.731
Authors: Beatriz Grinsztejn; Valdilea G Veloso; Ruth K Friedman; Ronaldo I Moreira; Paula M Luz; Dayse P Campos; José H Pilotto; Sandra W Cardoso; Jeanne C Keruly; Richard D Moore Journal: AIDS Date: 2009-10-23 Impact factor: 4.177
Authors: Carina Cesar; Bryan E Shepherd; Alejandro J Krolewiecki; Valeria I Fink; Mauro Schechter; Suely H Tuboi; Marcelo Wolff; Jean W Pape; Paul Leger; Denis Padgett; Juan Sierra Madero; Eduardo Gotuzzo; Omar Sued; Catherine C McGowan; Daniel R Masys; Pedro E Cahn Journal: PLoS One Date: 2010-06-01 Impact factor: 3.240